



## **IcanoMAB announces a novel IL-18 signaling blocker (anti-IL-1R7) ready for development for the treatment of the Cytokine-Release-Syndrome in late-stage Covid-19**

- **Positive regulatory advice received for development plan to provide POC in late-stage COVID-19 patients**
- **Additional opportunities in indications related to Cytokine-Release Syndrome, e.g., ARDS, MAS and acute inflammatory diseases**
- **Pre-clinical proof-of-concept recently published with Charles Dinarello, University of Colorado, Denver**
- **Partner discussions in preparation to exploit full therapeutic potential**

**Polling, Germany – May 17, 2021:** IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision antibodies for the treatment of cancer, immune-system related diseases and COVID-19, today announced that it has received positive regulatory advice for the clinical development path of its anti-IL-1R7 antibody in late-stage COVID-19. In addition, IcanoMAB has published the pre-clinical proof-of-concept for the anti-IL-1R7 antibody that blocks the signal transduction of the interleukin-18 (IL-18) receptor.

Recently, IcanoMAB achieved positive regulatory advice for its clinical development plan in late-stage COVID-19. IcanoMAB's scientific approach, pre-clinical evidence and development plan were supported as presented.

Systemic inflammation can result in severe pathologies with high mortality. The Cytokine-Release-Syndrome has been observed in late-stage COVID-19 patients and other diseases exhibiting systemic hyper-inflammation. Elevated IL-18, a proinflammatory cytokine belonging to the IL-1 family, initiating the avalanche of effects in the Cytokine-Release-Syndrome, is known to correlate with the severity of late-stage COVID-19. IcanoMAB's novel humanized monoclonal anti-IL-1R7 (=IL-18 receptor beta chain) antibody specifically blocks the signal transduction of pro-inflammatory IL-18 and has been developed in closed collaboration with Charles Dinarello. Pre-clinical Proof-of-Concept was provided and recently published ([www.jbc.org/article/S0021-9258\(21\)00416-6/fulltext](http://www.jbc.org/article/S0021-9258(21)00416-6/fulltext)) by scientific partners at the Dinarello Lab, Department of Medicine, University of Colorado Denver, Aurora, Colorado/USA and Department of Medicine, the Radboud University Medical Center, Nijmegen/The Netherlands and the Department of Infectious Disease and Institute of Clinical Medicine Aarhus University Hospital, Aarhus/Denmark.

Additional therapeutic indications will include diseases related to the Cytokine-Release-Syndrome, e.g., Acute Respiratory Distress Syndrome (ARDS) and Macrophage Activation Syndrome (MAS) or other acute inflammatory diseases, e.g., IBD, Gout and Asthma.

IcanoMAB is currently entering discussions with interested parties for a development partnership of its anti IL-1R7 antagonist antibody.

Ends

**Contacts:****IcanoMAB GmbH**

Tassilostr. 2, 82398 Polling, Germany

+49 881 39 90 89 40

[info@IcanoMAB.com](mailto:info@IcanoMAB.com)

**About IcanoMAB**

IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system related diseases and Covid-19. The company is developing its proprietary clinical candidates to exploit novel approaches improving clinical outcome in immuno-oncology, solid tumors and immunology and inflammation.

IcanoMAB was founded by highly experienced entrepreneurs and scientists with a track record of successful drug development in multiple companies including Boehringer Mannheim, Roche, MAB Discovery, Xantos Biomedicine, JSB Partners, Novartis and TVM Capital Life Science. The company was founded by MAB Discovery, represented by Dr. Stephan Fischer, CEO, Dr. Ulrich Pessara and Daniel Parera, MD.

IcanoMAB is headquartered in Polling, Germany.

For more information on IcanoMAB, please visit the company's website at [www.IcanoMAB.com](http://www.IcanoMAB.com)